专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2014179200A1 ORF2 PROTEIN OF PCV2 SUBTYPE A (PCV2A) FOR USE IN CROSS-PROTECTION 审中-公开
标题翻译：用于交叉保护的PCV2亚型A（PCV2A）的ORF2蛋白质
公开(公告)号：WO2014179200A1
公开(公告)日：2014-11-06
申请号：PCT/US2014/035640
申请日：2014-04-28
申请人： BOEHRINGER INGELHEIM VETMEDICA, INC. , HAIWICK, Gregory , HERNANDEZ, Luis , JOHNSON, Wesley Scott , MUEHLENTHALER, Christine Margaret , VAUGHN, Eric Martin
发明人： HAIWICK, Gregory , HERNANDEZ, Luis , JOHNSON, Wesley Scott , MUEHLENTHALER, Christine Margaret , VAUGHN, Eric Martin
IPC分类号： A61K39/12 , C07K14/01
CPC分类号： A61K39/12 , A61K39/0208 , A61K39/0258 , A61K39/04 , A61K39/05 , A61K39/08 , A61K39/085 , A61K39/092 , A61K39/145 , A61K39/215 , A61K39/23 , A61K39/235 , A61K39/245 , A61K2039/545 , A61K2039/552 , A61K2039/55555 , A61K2039/70 , C12N7/00 , C12N2750/10022 , C12N2750/10034
摘要： Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype a (PCV2a) ORF2 proteins or immunogenic compositions comprising a PCV2a ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of a different subtype, the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of a different subtype, or the prevention or treatment of a disease caused by an infection with PCV2 of a different subtype.
摘要翻译：公开了用不同PCV2亚型控制PCV2感染的疫苗接种方法。具体地说，将PCV2亚型（PCV2a）ORF2蛋白质或包含PCV2a ORF2蛋白质的免疫原性组合物用于治疗或预防不同亚型的PCV2感染的方法，减少，预防或治疗由不同亚型的PCV2的感染，或预防或治疗由不同亚型的PCV2的感染引起的疾病。

2. 发明申请

WO2014167060A1 Fusion polypeptides and vaccines 审中-公开
标题翻译：融合多肽和疫苗
公开(公告)号：WO2014167060A1
公开(公告)日：2014-10-16
申请号：PCT/EP2014/057287
申请日：2014-04-10
申请人： CEVA SANTE ANIMALE
发明人： SATO, Takanori
IPC分类号： A61K39/12 , A61K39/385
CPC分类号： C07K14/005 , A61K39/00 , A61K39/12 , A61K39/385 , A61K2039/552 , A61K2039/6075 , C07K2319/02 , C12N7/00 , C12N2710/24021 , C12N2710/24043 , C12N2710/24122 , C12N2750/10022 , C12N2750/10034 , C12N2750/10071
摘要： The present invention relates to novel immunogenic polypeptides and their use in vaccine compositions. The invention also relates to nucleic acids,vectors and cells which express the polypeptides and the uses thereof. The polypeptides of the invention more specifically comprise an immunogenic domain and a cell membrane addressing domain which is derived from a B5R gene. The invention is particularly suited to produce vaccines for non-human animals, particularly for vaccinating swine against PCV2 infection.
摘要翻译：本发明涉及新型免疫原性多肽及其在疫苗组合物中的用途。本发明还涉及表达多肽的核酸，载体和细胞及其用途。本发明的多肽更具体地包含衍生自B5R基因的免疫原性结构域和细胞膜寻址结构域。本发明特别适用于生产用于非人类动物的疫苗，特别是用于接种猪抵抗PCV2感染的疫苗。

3. 发明申请

WO2014089009A1 FUSION PROTEINS FOR USE AS IMMUNOGENIC ENHANCERS FOR INDUCING ANTIGEN-SPECIFIC T CELL RESPONSES 审中-公开
标题翻译：用作诱导抗原特异性T细胞应答的免疫增强物的融合蛋白
公开(公告)号：WO2014089009A1
公开(公告)日：2014-06-12
申请号：PCT/US2013/072753
申请日：2013-12-03
申请人： THEVAX GENETICS VACCINE CO., LTD. , HEALTHBANKS BIOTECH USA INC.
发明人： WU, Chia-Mao , CHANG, Hsiu-Kang
IPC分类号： A61K39/385 , A61K39/00 , A61K38/00
CPC分类号： C07K14/005 , A61K39/12 , A61K39/135 , A61K39/17 , A61K39/21 , A61K39/29 , A61K39/292 , A61K39/385 , A61K2039/57 , A61K2039/585 , A61K2039/6031 , C07K14/21 , C07K14/70596 , C07K14/81 , C07K2319/02 , C07K2319/04 , C07K2319/095 , C07K2319/33 , C07K2319/40 , C07K2319/55 , C12N9/1077 , C12N9/14 , C12N2710/20022 , C12N2710/20034 , C12N2730/10122 , C12N2730/10134 , C12N2750/10022 , C12N2750/10034 , C12N2760/18134 , C12N2770/24222 , C12N2770/24234 , C12N2770/24334 , C12N2770/32134 , C12Y204/02036 , C12Y306/05002 , Y02A50/386
摘要： A fusion protein for use as an immunogen enhancer for enhancing antigen-specific T cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain; (b) a protein transduction domain; and (c) an antigen of a pathogen, wherein the APC-binding domain or the CD91 receptor-binding domain is located at the N-terminus of the fusion protein, and the antigen of the pathogen is located at the C-terniinus of the protein transduction domain. The protein transduction domain is selected from the group consisting of: (i) a fusion polypeptide, comprising a T cell sensitizing signal-transducing peptide, a linker, and a translocation peptide; (it) a T cell-sensitizing signal-transducing peptide; and (iii) a translocation peptide of 34-112 amino acid residues in length.
摘要翻译：公开了用作增强抗原特异性T细胞应答的免疫原增强剂的融合蛋白。融合蛋白包括：（a）抗原呈递细胞（APC）结合结构域或CD91受体结合结构域; （b）蛋白转导结构域; 和（c）病原体的抗原，其中APC结合结构域或CD91受体结合结构域位于融合蛋白的N末端，并且病原体的抗原位于C-Terniinus 蛋白转导结构域。蛋白转导结构域选自：（i）包含T细胞致敏信号转导肽，接头和易位肽的融合多肽; （它）T细胞增敏信号转导肽; 和（iii）长度为34-112个氨基酸残基的易位肽。

4. 发明申请

WO2007094893A3 USE OF A PCV2 IMMUNOGENIC COMPOSITION FOR LESSENING CLINICAL SYMPTOMS IN PIGS 审中-公开
标题翻译：使用PCV2免疫组合物治疗小便中的临床症状
公开(公告)号：WO2007094893A3
公开(公告)日：2008-11-06
申请号：PCT/US2006062662
申请日：2006-12-28
申请人： BOEHRINGER INGELHEIM VETMED , ROOF MICHAEL B , HAYES PHILLIP WAYNE , EICHMEYER MARC , NITZEL GREG , SCHAEFFER MERRILL
发明人： ROOF MICHAEL B , HAYES PHILLIP WAYNE , EICHMEYER MARC , NITZEL GREG , SCHAEFFER MERRILL
IPC分类号： A61K39/00 , A61K39/12
CPC分类号： A61K39/12 , A61K2039/5252 , A61K2039/5256 , A61K2039/5258 , A61K2039/545 , A61K2039/552 , A61K2039/55516 , A61K2039/55555 , A61K2039/55566 , C12N7/00 , C12N2750/10022 , C12N2750/10023 , C12N2750/10034 , C12N2750/10051 , C12N2750/10071 , C12N2750/14143
摘要： The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopalhy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (51 nephritis and (6) reproductive disorders, e.g. abortion, stillbirths. mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.
摘要翻译：本发明涉及包含用于治疗几种临床表现（疾病）的猪圆环病毒2型（PCV2）抗原的免疫原性组合物的用途。优选地，临床表现与PCV2感染相关。优选地，它们包括淋巴结病，淋巴细胞减少和/或多核/巨细胞组织细胞。此外，临床症状包括与猪中的一种或多种以下症状相结合的淋巴结肿大：（1）间质性肺炎与小叶间水肿，（2）皮肤苍白或黄疸，（3）斑驳萎缩性肝脏，（4）胃溃疡，（51）肾炎和（6）生殖障碍，例如堕胎，死胎，木乃伊等。此外，临床症状包括通常已知与细胞内劳森氏菌感染相关的Pia样病变。

5. 发明申请

WO2008073464A3 EFFECTIVE METHOD OF TREATMENT OF PORCINE CIRCOVIRUS AND LAWSONIA INTRACELLULARIS INFECTIONS 审中-公开
标题翻译：有效的方法治疗猪环状病毒和Lawsonia细胞内感染
公开(公告)号：WO2008073464A3
公开(公告)日：2008-10-30
申请号：PCT/US2007025419
申请日：2007-12-11
申请人： BOEHRINGER INGELHEIM VETMED , FACHINGER VICKY , ELBERS KNUT
发明人： FACHINGER VICKY , ELBERS KNUT
IPC分类号： A61K39/295 , A61K39/00 , A61K39/02 , A61K39/12 , A61K39/42
CPC分类号： A61K39/02 , A61K39/105 , A61K39/12 , A61K2039/552 , A61K2039/70 , C07K14/005 , C12N7/00 , C12N2750/10022 , C12N2750/10034
摘要： The present invention relates to the use of porcine circovirus type 2 (PCV2) antigen and Lawsonia intracellularis (L.intracellularis) antigen for the prevention, reduction in severity of, lessening of the clinical symptoms associated therewith, reduced incidence in a herd, and treatment of swine against Porcine Circovirus Associated Diseases (PCVAD) and L.intracellularis associated diseases. In particular, the present invention provides a method for the treatment or prophylaxis of an animal against PCV2 infection and ileitis caused by L. intracellu
摘要翻译：本发明涉及猪圆环病毒2型（PCV2）抗原和胞内劳森菌（L.intracellularis）抗原用于预防，减轻其严重程度，减轻与其相关的临床症状，降低牛群发病率和治疗的猪抵抗猪圆环病毒相关疾病（PCVAD）和L.intracellularis相关疾病。具体地说，本发明提供了一种治疗或预防动物对由L. intracellu引起的PCV2感染和回肠炎的方法

6. 发明申请

WO2008081015A1 TREATMENT OF PRDC IN PIGS 审中-公开
标题翻译：皮肤中PRDC的治疗
公开(公告)号：WO2008081015A1
公开(公告)日：2008-07-10
申请号：PCT/EP2008/050012
申请日：2008-01-02
申请人： BOEHRINGER INGELHEIM VETMEDICA, INC. , FACHINGER, Vicky , ELBERS, Knut , KIXMOELLER, Marion , ORVEILLON, Francois-Xavier , FREIIN VON RICHTHOFEN, Isabelle , LISCHEWSKI, Axel
发明人： FACHINGER, Vicky , ELBERS, Knut , KIXMOELLER, Marion , ORVEILLON, Francois-Xavier , FREIIN VON RICHTHOFEN, Isabelle , LISCHEWSKI, Axel
IPC分类号： A61K39/12 , C07K14/01 , C12N15/866
CPC分类号： A61K39/12 , A61K2039/5256 , A61K2039/545 , A61K2039/552 , A61K2039/55555 , C12N7/00 , C12N2710/14043 , C12N2750/10022 , C12N2750/10034
摘要： The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (PCV2) antigen for the prevention and treatment of porcine respiratory disease complex (PRDC) in animals, preferably in pigs.
摘要翻译：本发明涉及包含猪圆环病毒2型（PCV2）抗原的免疫原性组合物在动物，优选猪中预防和治疗猪呼吸道疾病复合物（PRDC）的用途。

7. 发明申请

WO2007094893A2 USE OF A PCV2 IMMUNOGENIC COMPOSITION FOR LESSENING CLINICAL SYMPTOMS IN PIGS 审中-公开
标题翻译：使用PCV2免疫组合物治疗小便中的临床症状
公开(公告)号：WO2007094893A2
公开(公告)日：2007-08-23
申请号：PCT/US2006062662
申请日：2006-12-28
申请人： BOEHRINGER INGELHEIM VETMED , ROOF MICHAEL , HAYES PHILLIP , EICHMEYER MARC , NITZEL GREG , SCHAEFFER MERRILL
发明人： ROOF MICHAEL , HAYES PHILLIP , EICHMEYER MARC , NITZEL GREG , SCHAEFFER MERRILL
CPC分类号： A61K39/12 , A61K2039/5252 , A61K2039/5256 , A61K2039/5258 , A61K2039/545 , A61K2039/552 , A61K2039/55516 , A61K2039/55555 , A61K2039/55566 , C12N7/00 , C12N2750/10022 , C12N2750/10023 , C12N2750/10034 , C12N2750/10051 , C12N2750/10071 , C12N2750/14143
摘要： The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopalhy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (51 nephritis and (6) reproductive disorders, e.g. abortion, stillbirths. mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.
摘要翻译：本发明涉及包含用于治疗几种临床表现（疾病）的猪圆环病毒2型（PCV2）抗原的免疫原性组合物的用途。优选地，临床表现与PCV2感染相关。优选地，它们包括淋巴结病，淋巴细胞减少和/或多核/巨细胞组织细胞。此外，临床症状包括与猪中的一种或多种以下症状相结合的淋巴结肿大：（1）间质性肺炎与小叶间水肿，（2）皮肤苍白或黄疸，（3）斑驳萎缩性肝脏，（4）胃溃疡，（51）肾炎和（6）生殖障碍，例如堕胎，死胎，木乃伊等。此外，临床症状包括通常已知与细胞内劳森氏菌感染相关的Pia样病变。

8. 发明申请

WO01096377A2 VACCINE FOR CONGENITAL TREMORS IN PIGS 审中-公开
标题翻译：真菌用于疫苗的疫苗
公开(公告)号：WO01096377A2
公开(公告)日：2001-12-20
申请号：PCT/US2001/019220
申请日：2001-06-15
IPC分类号： G01N33/53 , A61K39/00 , A61K39/12 , A61K48/00 , A61P31/20 , C07K14/005 , C07K14/01 , C07K16/08 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N7/00 , C12N7/04 , C12N15/09 , C12P21/02 , C12Q1/68 , G01N33/564 , G01N33/566 , G01N33/569
CPC分类号： C07K14/005 , A61K39/00 , A61K2039/525 , A61K2039/53 , C12N2750/10022
摘要： The invention is based on the cloning of porcine circovirus (PCV) strains from pigs with congenital tremors. These results provide a first step for the development of diagnostic and therapeutic applications for congenital tremors in a pig. The diagnostic method comprises determining whether the pig has been infected by a porcine circovirus strain of type 1 or type 2. The invention further provides a method for the prevention or treatment of congenital tremors in a pig, which method comprises administering to the pig an effective amount of an immunogenic PCV 1 or PCV 2 polypeptide or of a nucleic acid encoding this polypeptide. Another subject of the invention is the new PCV nucleic acid sequences identified by the inventors and the polypeptides encoded by these sequences, as well as the new PCV isolates and immunogenic preparations thereof.
摘要翻译：本发明基于从先天性震颤猪的猪圆环病毒（PCV）菌株的克隆。这些结果提供了开发针对猪的先天性震颤的诊断和治疗应用的第一步。诊断方法包括确定猪是否已经被1型或2型猪圆环病毒感染。本发明还提供了一种预防或治疗猪中先天性震颤的方法，该方法包括对猪施用有效的免疫原性PCV 1或PCV 2多肽或编码该多肽的核酸的量。本发明的另一主题是本发明人鉴定的新的PCV核酸序列和由这些序列编码的多肽，以及新的PCV分离株及其免疫原性制剂。

9. 发明申请

WO99029871A2 CIRCOVIRUS SEQUENCES RELATED TO PIGLET WEIGHT LOSS DISEASE (PWD) 审中-公开
标题翻译：与重量损失疾病相关的循环序列
公开(公告)号：WO99029871A2
公开(公告)日：1999-06-17
申请号：PCT/FR1998/002634
申请日：1998-12-04
IPC分类号： A61K39/00 , A61K48/00 , C07K14/01 , C12N5/02 , C12N15/34 , C12N15/86 , C12N7/04 , C12N5/10 , C12N7/00 , A01K67/027 , C12Q1/68 , C07K16/08 , G01N33/569
CPC分类号： A61K39/12 , A01K2217/05 , A61K39/00 , A61K48/00 , A61K2039/525 , A61K2039/5252 , A61K2039/5254 , A61K2039/5256 , A61K2039/53 , A61K2039/55 , A61K2039/552 , A61K2039/55522 , A61K2039/55566 , A61K2039/58 , C07K14/005 , C07K2319/55 , C12N7/00 , C12N2710/14143 , C12N2750/10021 , C12N2750/10022 , C12N2750/10034 , C12N2750/10051 , C12N2750/10061 , G01N33/56983 , G01N2333/01 , G01N2469/20 , Y10T428/13
摘要： The invention concerns the genome sequence and the nucleotide sequences coding for the PWD circovirus polypeptides, such as said circovirus structural and non-structural polypeptides, and vectors including said sequences and cells or animals transformed by said vectors. The invention also concerns methods for detecting said nucleic acids or polypeptides and kits for diagnosing infection by a PWD circovirus. The invention further concerns a method for selecting compounds capable modulating the viral infection. Finally the invention concerns pharmaceutical, in particular vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of said vector for preventing and/or treating diseases by gene therapy.
摘要翻译：本发明涉及编码PWD圆环病毒多肽的基因组序列和核苷酸序列，例如所述圆环病毒结构和非结构多肽，以及包含所述序列的载体和由所述载体转化的细胞或动物。本发明还涉及用于检测所述核酸或多肽的方法以及用于诊断PWD圆环病毒感染的试剂盒。本发明还涉及一种选择能够调节病毒感染的化合物的方法。最后，本发明涉及用于预防和/或治疗由PWD圆环病毒引起的病毒感染的药物，特别是疫苗组合物，以及所述载体用于通过基因治疗预防和/或治疗疾病的用途。

10. 发明申请

WO1996041191A1 METHODS AND USES FOR APOPTIN 审中-公开
标题翻译： APOPTIN的方法和用途
公开(公告)号：WO1996041191A1
公开(公告)日：1996-12-19
申请号：PCT/NL1996000229
申请日：1996-06-07
申请人： AESCULAAP B.V.
发明人： AESCULAAP B.V. , NOTEBORN, Matheus, Hubertus, Maria
IPC分类号： G01N33/574
CPC分类号： C07K14/005 , A61K38/00 , A61K48/00 , C12N2750/10022 , G01N33/56983 , G01N33/574
摘要： This invention describes that apoptin fails to induce apoptosis in human normal cells. Besides, the invention describes that when normal cells are transformed, they become susceptible to the apoptin-induced apoptosis. The invention describes that apoptin induces in various human tumor cells a p53-distinct type of apoptosis, and cannot be blocked by a variety of apoptosis-inhibiting agents. The invention comprises an anti-tumor agent, which specifically kill tumor and not normal cells. It further provides the induction of cell death by means of gene therapy. Apoptin can induce apoptosis in non-human animal tumor cells. The invention also provides that in normal cells apoptin was found predominantly in the cytoplasm, while in tumor cells it was located in the nucleus. Besides, the invention comprises a diagnostic test for the determination of cell-transforming activity.
摘要翻译：本发明描述了凋亡素不能诱导人正常细胞凋亡。此外，本发明描述了当正常细胞转化时，它们变得易于凋亡蛋白诱导的细胞凋亡。本发明描述了凋亡素在各种人肿瘤细胞中诱导p53不同类型的凋亡，并且不能被多种凋亡抑制剂阻断。本发明包括特异性杀死肿瘤而不是正常细胞的抗肿瘤剂。它进一步提供通过基因治疗诱导细胞死亡。凋亡素可诱导非人动物肿瘤细胞凋亡。本发明还规定，在正常细胞中，凋亡素主要在细胞质中发现，而在肿瘤细胞中，其位于细胞核中。此外，本发明包括用于测定细胞转化活性的诊断试验。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式